To determine whether inhibition of either the ribosomal p70 S6 kinase or eIF4E pathways downstream of mTOR contributes to rapamycin-induced growth arrest clones of Rh30 rhabdomyosarcoma cells were selected for rapamycin resistance. Expression of c-Myc and anchorage-independent growth were enhanced in resistant cells. Resistance was unstable in each of 3 clones characterized. In resistant cells, as compared to parental cells, approximately 10-fold less 4E-BP was bound to eIF4E, and total cellular 4E-BP was markedly reduced. Levels of eIF4E were unchanged. Steady-state levels of 4E-BP transcript remained unaltered, but the rate of 4E-BP synthesis was reduced in resistant cells. In cells that reverted to rapamycin sensitivity, levels of total 4E-BP returned to those of parental cells. Compared to parental cells resistant clones had either similar or lower levels and activity of ribosomal p70 S6 kinase, but cMYC levels were elevated in both resistant and revertant clones. Several colon carcinoma cell lines with intrinsic rapamycin resistance were found to have low 4E-BP:eIF4E ratios. In stable clones of HCT8 carcinoma engineered to overexpress 4E-BP, rapamycin sensitivity increased markedly (> 1000-fold) as 4E-BP expression increased. These results suggest that the 4E-BP:eIF4E ratio is an important determinant of rapamycin resistance, and controls certain aspects of the malignant phenotype.
Introduction.
Rapamycin is a macrocyclic lactone antibiotic that potently inhibits the activation of T cells and the growth of many malignant cells in culture (1) (2) (3) (4) (5) . Rapamycin first binds to a cytosolic immunophilin, FKBP-12; this complex then binds to the target of rapamycin (TOR) and inhibits its kinase function (6) (7) (8) (9) . The mammalian target of rapamycin, mTOR (also designated FRAP, RAFT1, or RAPT), has been proposed to link mitogen stimulation to protein synthesis and cell cycle progression (10) . The signaling pathway downstream of mTOR bifurcates (11) ; hence, inhibition of mTOR signaling affects at least two separate pathways, both of which control translation of specific mRNA species.
In many cell lines, exposure to rapamycin results in a relatively small (~15% to 20%) decrease in overall protein synthesis but causes cell cycle arrest in G1.
Inhibition of mTOR's kinase activity blocks growth factor stimulation of ribosomal p70 S6 kinase and leads to hypophosphorylation of the eukaryotic initiation factor (eIF) 4E-binding proteins (4E-BPs) 1-3. The 4E-BP isoforms are considered to be direct substrates of mTOR kinase activity in cells (10, 12) . At least two sites (Thr37, Thr46) on the 4E-BPs are phosphorylated by mTOR, whereas other sites (Ser 60, Thr70, Ser83) may be phosphorylated by mTOR (13, 14) or by other kinases (15) (16) (17) (18) .
Hypophosphorylated 4E-BP family members tightly bind eIF4E, preventing its association with the multifunctional scaffolding protein eIF4G (19, 20) . In serum-starved quiescent cells, stimulation with growth factor or serum leads to phosphorylation of 4E-BPs and their resultant dissociation from eIF4E, thereby facilitating assembly of the multisubunit complex (eIF4F) and efficient translation of mRNA having highly structured 5′-untranslated regions (21). Rapamycin prevents phosphorylation of 4E-BPs and prevents dissociation of the 4E-BP:eIF4E complex in growth factor−stimulated cells.
The activity of mTOR is directly (22,23) or indirectly (24) required for activation of ribosomal p70 S6 kinase through phosphorylation of its rapamycin-sensitive site (Thr-229) (25). Substitution of this residue abrogates rapamycin sensitivity. However, it is less certain whether inhibition of p70 S6 kinase activation is a crucial determinant of the action of rapamycin. Rapamycin inhibited the proliferation of embryonic stem cells in which p70 S6 kinase was disrupted (26); this finding suggests that other signaling events downstream of mTOR are crucial to growth inhibition.
Resistance to rapamycin has been extensively studied in the yeast Saccharomyces cerevisiae. Dominant mutations in the rapamycin target, TOR, that prevent its binding to the FKBP12-rapamycin complex have been reported to cause resistance (27-29). In addition, a recessive resistance phenotype was reported to be associated with decreased expression of RBP1, a homolog of mammalian FKBP-12, or with a mutation altering Tyr-89; either of these changes decreased the formation of the rapamycin complex (30).
In mammalian cells selected for resistance to rapamycin after mutagenesis, resistance is associated with a dominant phenotype consistent with a mutant mTOR (31) that has decreased binding affinity for the FKBP-rapamycin complex. Expression of a mutant mTOR (Ser2035Ile) that has reduced affinity for this complex confers marked resistance (32,33). Rapamycin resistance is also reported to be associated with loss of the CDK inhibitor p27
Kip1 (34) and to be enhanced in the cells of patients with ataxia-telangiectasia (35). Intrinsic resistance to rapamycin does not correspond to altered phosphorylation of by guest on July 16, 2017 http://www.jbc.org/ Downloaded from 4E-BPs (36). This finding is consistent with our previous report that mTOR-dependent activation of p70 S6 kinase does not coincide with cellular sensitivity to rapamycin (37).
Our studies also found similar levels of mTOR protein, drug uptake, and drug retention in rapamycin-sensitive and rapamycin-resistant cells. Intrinsic resistance appears to result partially from redundant signaling. For example, exogenous IGF-I completely prevents rapamycin-induced apoptosis and allows proliferation, although mTOR signaling is inhibited (33).
Resistance to rapamycin may be acquired through mutations in FKBP-12, mTOR, or p70 S6 kinase. It remains unclear, however, whether rapamycin sensitivity (growth inhibition of tumor cells) requires the inhibition of both the p70 S6 kinase and eIF4E pathways or of only one of these pathways. To answer this question, we analyzed Rh30 rhabdomyosarcoma cells selected for resistance to rapamycin. We found resistance to be unstable and to be associated with decreased intracellular 4E-BP. We observed no alterations in mTOR signaling to p70 S6 kinase or in sensitivity to inhibition by rapamycin. As expected with dysregulation of eIF4E, rapamycin-resistant cells showed increased intracellular c-Myc and significantly enhanced anchorage-independent growth.
Further, overexpression of 4E-BP1 dramatically sensitized colon carcinoma cells that are intrinsically resistant to rapamycin.
was transferred to a separate well of a 24-well cluster plate containing rapamycin-free medium. The next day, 5000 ng/ml rapamycin in fresh medium was added to each well.
Ten days later, when clone C4 had formed a monolayer, it was transferred to a 25-cm 2 flask containing 5000 ng/ml rapamycin and was subsequently maintained in this concentration of rapamycin.
Proliferation inhibition assays. Cells (10 5 /well) were plated in triplicate on 6-well culture plates The next day, serial dilutions of rapamycin were added to the wells; cells were then incubated for 7 days. Cells were lysed under hypotonic conditions, as described previously, and nuclei were enumerated by using a Coulter counter (4,33). diphenyltetrazolium bromide, Sigma St. Louis, MO) )color reagent (0.5 mg/ml in sterile PBS) was added to each well, and cells were incubated overnight at 37°C and 5% CO 2 .
The next day, the stained colonies were counted and their areas were measured by using 1µg/ml aprotinin, 1 µg /ml pepstatin, 1 µg/ml leupeptin, 2 mM benzamidine, and 10 µg/ml soybean trypsin inhibitor). Lysis was accomplished by three freeze-thaw cycles.
To bind eIF4E, 25 µl of 7-methyl-GTP-Sepharose (Pharmacia Biotech) was added to the lysates, which were then incubated overnight on a rotator at 4ºC. The complexes were pelleted by centrifugation and washed three times with lysis buffer. To elute eIF4E from by guest on July 16, 2017 http://www.jbc.org/ Downloaded from the Sepharose, 50 µl of SDS-PAGE loading buffer was added to the samples, which were then heated to 95ºC for 3 min. Samples were analyzed for 4E-BP and eIF4E by SDS-PAGE and Western blot with standard chemiluminescent methods, as described above.
Assay of ribosomal p70 S6 kinase activity: Assays were performed as described previously (37). Briefly, 2 × 10 6 cells were seeded in 75-cm 2 flasks and allowed to attach overnight. Initial experiments determined that exposure to rapamycin for 1 hr resulted in maximal inhibition of p70 S6 kinase activity. Cells were exposed for 1 hr to rapamycin (100 ng/ml), washed extensively, and lysed by gentle rocking at 4°C in 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM EGTA, 1 mM PMSF, 1mM Na 3 VO 4 , and 1 mM NaF) containing 10 µg/ml each of aprotinin, leupeptin, and pepstatin. Lysates were centrifuged at 15,000 × g for 5 min at Ready Gel (Bio-Rad, Hercules, CA). The gel was dried at 80°C for 1 hr, and the radiolabeled products were quantified by scanning of the resulting autoradiograms.
Stable transfection of HCT8 colon carcinoma cells with 4E-BP expression vector.
HCT-8 cells were plated at a density of 3 × and 2 mM L-glutamine. After 48 hr, fresh medium containing 500 µg/ml G418 was added. Surviving colonies were allowed to grow for two weeks and were then ring-cloned and placed in 12.5-cm 2 flasks in 2 ml medium containing 10% dialyzed FBS, 2 mM Lglutamine, and 500 µg/ml G418. Ten colonies were selected for further evaluation. 
Results

Selection of rapamycin-resistant clones. The alveolar rhabdomyosarcoma cell line
Rh30 is exquisitely sensitive to rapamycin (4,33) and has been used as a model system for studying acquired rapamycin-resistant phenotypes. Cells were grown in increasing concentrations of rapamycin to obtain lines that proliferated in the presence of 5000 or 10,000 ng/ml rapamycin (IC 50 ~10,000-fold to 20,000-fold greater than that of the parental lines). Three clones were further characterized: Rapa10K and C2, which were selected without mutagenesis, and C4, which was selected after treatment with EMS.
Rapamycin resistance is unstable. Rapa10K, C2, and C4 cells growing in rapamycin (10,000 ng/ml) were washed extensively in HBSS, plated, and allowed to attach to the surface of the flask overnight in drug-free medium. The cells were then cultured for 7
additional days in the presence of drug before they were stained and enumerated or were grown without rapamycin for 6 or 10 weeks and were then retested for sensitivity. To determine whether the dramatic decrease in 4E-BP binding to eIF4E in rapamycinresistant clones was caused by suppression of 4E-BP1 expression, we assayed 4E-BP1 in total cell extracts. To obtain results that were comparable to those obtained in the previous experiment, we used parallel conditions of serum starvation and IGF-I stimulation with or without rapamycin. The results of Western blot analyses demonstrated that resistance was associated with substantially decreased levels of 4E-BP1 (Fig. 3A) . In Rapa10K cells, the quantity of 4E-BP1 was markedly less than that of eIF4E or β-tubulin and was barely detectable. Rapa10K/Rev cells contained more 4E-BP1 than did Rapa10K but less than did parental cells. Essentially identical results were obtained by using a polyclonal antibody to the highly conserved carboxyl terminus of 4E-BP that recognizes all 4E-BP isoforms (data not shown). Hence, results obtained with isoform-specific antibody apply to all 4E-BPs.
Northern blot analysis showed no decrease in steady-state levels of 4E-BP transcript in Rh30, Rapa10K, and Rapa10K/Rev cells (Fig. 3B) . Thus, 4E-BP protein levels in resistant clones appear to be suppressed through a posttranscriptional mechanism.
Rapamycin-resistant C2 cells also showed reduced levels of 4E-BP protein, whereas rapamycin-sensitive C2-Rev contained levels of 4E-BPs similar to those in Rh30 cells (Fig. 3C) . Similar results were obtained with C4 and C4-Rev clones (not shown).
Collectively, these results suggest that acquired resistance to rapamycin is a result of Resistance is not associated with consistent changes in the p70 S6 kinase pathway.
To determine whether the ribosomal p70 S6 kinase pathway downstream of mTOR is altered in rapamycin-resistant cells, we used two assays. The quantity and activity of p70 S6 kinase were determined in parental rapamycin-resistant clones and in their revertant clones. In resistant clones, quantities of p70 S6 kinase were similar to (Rapa10K) or less (C2, and C4) than those in wild-type Rh30 cells after adjustment for protein loading ( 
Malignancy-associated characteristics are increased in rapamycin-resistant cells.
Rapamycin-resistant and revertant clones exhibited enhanced anchorage-independent growth in soft agar, which is consistent with dysregulation of c-Myc. Table 1 These results are consistent with previous reports that overexpression of eIF4E causes malignant transformation (41-43).
Overexpression of 4E-BP reverses intrinsic resistance to rapamycin. The findings above implicate a low 4E-BP:eIF4E ratio in resistance to rapamycin. If so, then overexpression of 4E-BP could potentially restore rapamycin sensitivity to Rapa10K cells. However, the selection of stable clones that overexpress 4E-BP would necessitate growth in rapamycin-free medium, which in turn would rapidly induce reversion to rapamycin sensitivity (Fig. 1) . As an alternative approach, we examined the 4E-BP:eIF4E ratio in a series of colon adenocarcinoma cells shown to be highly resistant to rapamycin (4) . Fig. 7A shows quantities of 4E-BP and eIF4E relative to tubulin in six colon carcinoma lines intrinsically resistant to rapamycin (IC 50 1280 to >10,000 ng/ml) and three tumor cell lines sensitive to rapamycin (Rh18, Rh30, SJ-G2; IC 50 0.1 to 0.5 ng/ml).
Clearly, in four of the colon carcinoma lines, the ratio of 4E-BP:eIF4E is low, consistent with resistance, whereas in the GC 3 and VRC 5 colon carcinoma cells, the ratio is similar to that in sensitive cells. Hence, a low 4E-BP:eIF4E ratio cannot account for intrinsic resistance to rapamycin in either GC 3 or VRC 5 cell lines. To determine whether an increase in the amount of 4E-BP could sensitize cells to rapamycin, we transfected HCT8 cells with a 4E-BP expression plasmid and selected stable clones by growth in medium containing G418. As shown in Fig. 7B , several clones (#2, 4, and 5) were identified that had increased expression of 4E-BP, whereas two G418-resistant clones (#1 and 3) had 4E-BP levels similar to that of parental HCT-8 cells. Levels of eIF4E were similar in all clones identified. The rapamycin sensitivity of each clone is shown in Fig. 6C . Cells were grown in increasing concentrations of rapamycin (0-10,000 ng/ml), and colonies were counted after 7 days. HCT8 was highly resistant to rapamycin, as expected, as were clones C1 and C3, which did not overexpress 4E-BP (IC 50 > 10,000 ng/ml). In contrast, clones C2, C5, and C4 were sensitive to rapamycin, having IC 50 values of 5, 8, and 30 ng/ml, respectively. The rapamycin sensitivity corresponded to 4E-BP:eIF4E ratios in these clones.
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Discussion
The work reported here provides the first demonstration that acquired resistance-and, in some cases, intrinsic resistance-to rapamycin in malignant cells is related to a low cellular ratio of 4E-BP to eIF4E. Further, we have shown that in Rapa10K cells, the decreased quantity of 4E-BP is caused in part by a reduced rate of 4E-BP synthesis.
Because rapamycin potently inhibits T-cell activation, it has been extensively used as an
immunosuppressant (1- We demonstrated previously that intrinsic resistance to rapamycin is not associated with elevated mTOR levels or decreased drug accumulation (37). In Rh30 cells, sensitivity to rapamycin was associated with rapamycin-induced inhibition of c-Myc translation (37), and acquired resistance was associated with increased c-Myc expression. The studies described here sought to further characterize the mechanism of resistance and to identify Ras also mediates eIF4E-induced transformation (49), and increased eIF4E expression has been proposed as a contributor to malignant progression (50). Rh30 cells express the sought a cell line with constitutive low expression of 4E-BP. We had previously identified colon carcinoma cell lines that have high intrinsic resistance to rapamycin (4).
Of the six tumor lines examined, four had very low levels of 4E-BP. In contrast, levels of eIF4E in sensitive tumor cell lines were similar to those in resistant tumor cell lines.
These findings suggested that low 4E-BP:eIF4E ratios might represent one mechanism of intrinsic resistance in colon cancer cell lines. To test this hypothesis directly, we selected HCT8 clones that stably expressed 4E-BP. Three clones overexpressed 4E-BP, whereas two had 4E-BP levels similar to those of parental HCT8 cells. The growth rate and colony formation characteristics of all the clones were similar. However, the clones that overexpressed 4E-BP were markedly more sensitive to rapamycin. The C2 and C5
clones, which had the highest levels of 4E-BP expression, had IC 50 values of only approximately 5 ng/ml rapamycin. In contrast, the IC 50 values of clones that did not overexpress 4E-BP were > 10,000 ng/ml. These results support the premise that a decreased 4E-BP:eIF4E ratio may be a determinant of intrinsic or acquired resistance.
Further, it is the eIF4E pathway, rather than the p70 S6 kinase pathway, that is crucial to rapamycin-induced growth inhibition, at least in Rh30 and HCT8 cells. Figure legends. Fig. 1 . Rapamycin resistance is unstable in the absence of selection pressure.
A. Rapamycin-resistant clones, Rapa10K (l), C2 (n), and C4 (‚) were selected for ability to proliferate in 10,000 ng/ml rapamycin. Drug was removed, cells were grown overnight, and sensitivity to rapamycin was determined at that time ( ng/ml at 16 hours, 121 ng/ml at 6 weeks, and 2.9 ng/ml at 10 weeks. Each point represents the mean ± SD of three determinations. C. Sensitivity to rapamycin. Cells were plated at low density in increasing concentrations of rapamycin, and colonies were counted after 7 days of exposure to rapamycin. Symbols: Parental HCT8 (˜) and clones C1 (™), C2 (¢), C3(£), C4(p), and C5(r). Each point is the mean ± SD of three determinations.
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